BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

282 related articles for article (PubMed ID: 34167951)

  • 21. Expression of SESN1, UHRF1BP1, and miR-377-3p as prognostic markers in mutated TP53 squamous cell carcinoma of the head and neck.
    El Baroudi M; Machiels JP; Schmitz S
    Cancer Biol Ther; 2017 Oct; 18(10):775-782. PubMed ID: 28886272
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Whole exome sequencing uncovers HRAS mutations as potential mediators of resistance to metronomic chemotherapy.
    Sambath J; Noronha V; Manda SS; Mishra R; Chandrani P; Patil V; Menon N; Chougule A; Ramachandran V; Limaye S; Kuriakose MA; Banavali SD; Kumar P; Prabhash K
    Gene; 2024 Jan; 893():147952. PubMed ID: 37918550
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Afatinib against Esophageal or Head-and-Neck Squamous Cell Carcinoma: Significance of Activating Oncogenic HER4 Mutations in HNSCC.
    Nakamura Y; Togashi Y; Nakahara H; Tomida S; Banno E; Terashima M; Hayashi H; de Velasco MA; Sakai K; Fujita Y; Okegawa T; Nutahara K; Hamada S; Nishio K
    Mol Cancer Ther; 2016 Aug; 15(8):1988-97. PubMed ID: 27207775
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Expression of TP53 mutation-associated microRNAs predicts clinical outcome in head and neck squamous cell carcinoma patients.
    Ganci F; Sacconi A; Bossel Ben-Moshe N; Manciocco V; Sperduti I; Strigari L; Covello R; Benevolo M; Pescarmona E; Domany E; Muti P; Strano S; Spriano G; Fontemaggi G; Blandino G
    Ann Oncol; 2013 Dec; 24(12):3082-8. PubMed ID: 24107801
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Signaling via ErbB2 and ErbB3 associates with resistance and epidermal growth factor receptor (EGFR) amplification with sensitivity to EGFR inhibitor gefitinib in head and neck squamous cell carcinoma cells.
    Erjala K; Sundvall M; Junttila TT; Zhang N; Savisalo M; Mali P; Kulmala J; Pulkkinen J; Grenman R; Elenius K
    Clin Cancer Res; 2006 Jul; 12(13):4103-11. PubMed ID: 16818711
    [TBL] [Abstract][Full Text] [Related]  

  • 26. RhoC mediates epidermal growth factor-stimulated migration and invasion in head and neck squamous cell carcinoma.
    Tumur Z; Katebzadeh S; Guerra C; Bhushan L; Alkam T; Henson BS
    Neoplasia; 2015 Jan; 17(1):141-51. PubMed ID: 25622907
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Enhanced cell migration and apoptosis resistance may underlie the association between high SERPINE1 expression and poor outcome in head and neck carcinoma patients.
    Pavón MA; Arroyo-Solera I; Téllez-Gabriel M; León X; Virós D; López M; Gallardo A; Céspedes MV; Casanova I; López-Pousa A; Mangues MA; Quer M; Barnadas A; Mangues R
    Oncotarget; 2015 Oct; 6(30):29016-33. PubMed ID: 26359694
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HOXB5 acts as an oncogenic driver in head and neck squamous cell carcinoma via EGFR/Akt/Wnt/β-catenin signaling axis.
    Lee K; Chang JW; Oh C; Liu L; Jung SN; Won HR; Kim YI; Rha KS; Koo BS
    Eur J Surg Oncol; 2020 Jun; 46(6):1066-1073. PubMed ID: 31864826
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Excavating novel diagnostic and prognostic long non-coding RNAs (lncRNAs) for head and neck squamous cell carcinoma: an integrated bioinformatics analysis of competing endogenous RNAs (ceRNAs) and gene co-expression networks.
    Yang L; Lu P; Yang X; Li K; Chen X; Qu S
    Bioengineered; 2021 Dec; 12(2):12821-12838. PubMed ID: 34898376
    [TBL] [Abstract][Full Text] [Related]  

  • 30. MAPK pathway mutations in head and neck cancer affect immune microenvironments and ErbB3 signaling.
    Ngan HL; Liu Y; Fong AY; Poon PHY; Yeung CK; Chan SSM; Lau A; Piao W; Li H; Tse JSW; Lo KW; Chan SM; Su YX; Chan JYK; Lau CW; Mills GB; Grandis JR; Lui VWY
    Life Sci Alliance; 2020 Jun; 3(6):. PubMed ID: 32381551
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Signatures of somatic mutations and gene expression from p16INK4A positive head and neck squamous cell carcinomas (HNSCC).
    Saba NF; Dinasarapu AR; Magliocca KR; Dwivedi B; Seby S; Qin ZS; Patel M; Griffith CC; Wang X; El-Deiry M; Steuer CE; Kowalski J; Shin DM; Zwick ME; Chen ZG
    PLoS One; 2020; 15(9):e0238497. PubMed ID: 32986729
    [TBL] [Abstract][Full Text] [Related]  

  • 32. TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
    Hajek M; Sewell A; Kaech S; Burtness B; Yarbrough WG; Issaeva N
    Cancer; 2017 May; 123(10):1778-1790. PubMed ID: 28295222
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Genomic analysis of head and neck squamous cell carcinoma cell lines and human tumors: a rational approach to preclinical model selection.
    Li H; Wawrose JS; Gooding WE; Garraway LA; Lui VW; Peyser ND; Grandis JR
    Mol Cancer Res; 2014 Apr; 12(4):571-82. PubMed ID: 24425785
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Epidermal growth factor receptor (EGFR) and squamous cell carcinoma of the skin: molecular bases for EGFR-targeted therapy.
    Uribe P; Gonzalez S
    Pathol Res Pract; 2011 Jun; 207(6):337-42. PubMed ID: 21531084
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mutational landscape of gingivo-buccal oral squamous cell carcinoma reveals new recurrently-mutated genes and molecular subgroups.
    India Project Team of the International Cancer Genome Consortium
    Nat Commun; 2013; 4():2873. PubMed ID: 24292195
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of actionable somatic mutations on racial/ethnic disparities in head and neck cancer prognosis.
    Wu ES; Park JY; Zeitouni JA; Gomez CR; Reis IM; Zhao W; Kwon D; Lee E; Nelson OL; Lin HY; Franzmann EJ; Savell J; McCaffrey TV; Goodwin WJ; Hu JJ
    Head Neck; 2016 Aug; 38(8):1234-41. PubMed ID: 27028310
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The Clinical Significance of Dickkopf Wnt Signaling Pathway Inhibitor Gene Family in Head and Neck Squamous Cell Carcinoma.
    Hu Y; Liu M; Xu S; Li S; Yang M; Su T; Yuan Z; Peng H
    Med Sci Monit; 2020 Nov; 26():e927368. PubMed ID: 33281184
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A Metabolic Gene Signature to Predict Overall Survival in Head and Neck Squamous Cell Carcinoma.
    Wu ZH; Tang Y; Zhou Y
    Mediators Inflamm; 2020; 2020():6716908. PubMed ID: 33456371
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical significance and biological functions of chemokine CXCL3 in head and neck squamous cell carcinoma.
    Guan J; Weng J; Ren Q; Zhang C; Hu L; Deng W; Lu S; Dong X; Li W; Li Y; Wang W
    Biosci Rep; 2021 Dec; 41(12):. PubMed ID: 34870709
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prognostic significance of epidermal growth factor receptor phosphorylation and mutation in head and neck squamous cell carcinoma.
    Hama T; Yuza Y; Saito Y; O-uchi J; Kondo S; Okabe M; Yamada H; Kato T; Moriyama H; Kurihara S; Urashima M
    Oncologist; 2009 Sep; 14(9):900-8. PubMed ID: 19726454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.